
Ebolavirus Infections (Ebola Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Ebolavirus Infections (Ebola Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2022, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.
Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 6, 60, 24 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 5, 13 and 8 molecules, respectively.
Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2022, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.
Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 6, 60, 24 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 5, 13 and 8 molecules, respectively.
Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
203 Pages
- Introduction
- Global Markets Direct Report Coverage
- Ebolavirus Infections (Ebola Hemorrhagic Fever) – Overview
- Ebolavirus Infections (Ebola Hemorrhagic Fever) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Ebolavirus Infections (Ebola Hemorrhagic Fever) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ebolavirus Infections (Ebola Hemorrhagic Fever) – Companies Involved in Therapeutics Development
- Abivax SA
- AIkido Pharma Inc
- AlphaVax Inc
- AnGes Inc
- ANP Technologies Inc
- AntoXa Corp
- Arisan Therapeutics Inc
- Auro Vaccines LLC
- Bharat Biotech Ltd
- BioComo Inc
- BioCryst Pharmaceuticals Inc
- BioFactura Inc
- Biotron Ltd
- Celdara Medical LLC
- Chicago Biosolutions Inc
- Cocrystal Pharma Inc
- Collaborations Pharmaceuticals Inc
- Emergent BioSolutions Inc
- Emergex Vaccines Holding Ltd
- Fab’entech SA
- Fibroplate Inc
- Flow Pharma Inc
- Fox Chase Chemical Diversity Center Inc
- Galactica Biotech Ltd
- Gamaleya Federal Research Center of Epidemiology and Microbiology
- GeoVax Labs Inc
- Gilead Sciences Inc
- Global BioLife Inc Ltd
- Greffex Inc
- H&P Labs Inc
- ImmunityBio Inc
- Inovio Pharmaceuticals Inc
- Integral Molecular Inc
- Integrated BioTherapeutics Inc
- IntelliStem Technologies Inc
- Johnson & Johnson
- Mapp Biopharmaceutical Inc
- Merck & Co Inc
- Microbiotix Inc
- Micropharm Ltd
- Novavax Inc
- Nykode Therapeutics AS
- Oita University Institute of Advanced Medicine Inc
- OncXerna Therapeutics Inc
- Orgenesis Inc
- Ostrich Pharma USA Inc
- Palisades Therapeutics
- PanThera Biopharma LLC
- Phelix Therapeutics LLC
- Phoenix Biotechnology Inc
- Public Health Vaccines LLC
- Regeneron Pharmaceuticals Inc
- ReVacc Biotech
- Riboscience LLC
- Rodos BioTarget GmbH
- SAB Biotherapeutics Inc
- Secarna Pharmaceuticals GmbH & Co KG
- Selva Therapeutics Inc
- Sihuan Pharmaceutical Holdings Group Ltd
- Soligenix Inc
- TFF Pharmaceuticals Inc
- Tiba Biotech LLC
- Tonix Pharmaceuticals Holding Corp
- Uvax Bio LLC
- Vaxeal Holding SA
- Vir Biotechnology Inc
- XBiotech Inc
- Xenothera SAS
- Yaso Therapeutics Inc
- Yisheng Biopharma Co Ltd
- Zalgen Labs LLC
- Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drug Profiles
- (atoltivimab + maftivimab + odesivimab) – Drug Profile
- (cosfroviximab + larcaviximab + porgaviximab) – Drug Profile
- (Ebola + Lassa Fever + Marburg) vaccine – Drug Profile
- (Ebola + Marburg) (bivalent) vaccine – Drug Profile
- (Ebola + Marburg) (trivalent) vaccine – Drug Profile
- (Ebola + Marburg) (virus like particle) vaccine – Drug Profile
- (Ebola + Marburg) vaccine – Drug Profile
- ABX-544 – Drug Profile
- ACLS-2L2 – Drug Profile
- ANP-015 – Drug Profile
- ANP-803 – Drug Profile
- Antibodies for Ebola and Marburg Viral Infections – Drug Profile
- Antibodies for Viral Infections – Drug Profile
- Antibody for Ebola Viral Infection – Drug Profile
- ARD-5 – Drug Profile
- bavituximab – Drug Profile
- BC-0007 – Drug Profile
- Bi-specific Monoclonal Antibodies for Ebola and Marburg Infections – Drug Profile
- Bi-specific Monoclonal Antibodies to Inhibit Glycoproteins for Ebola Viral Infections – Drug Profile
- CA-45 – Drug Profile
- cepharanthine – Drug Profile
- CM-JLD – Drug Profile
- CMSV-1 – Drug Profile
- DLANA-14 – Drug Profile
- Drugs for Viral Infections – Drug Profile
- Drugs to Inhibit Cathepsin B for Ebola Viral Infections – Drug Profile
- Ebola – Drug Profile
- Ebola (virus like particle) vaccine – Drug Profile
- ebola [ankara bavarian nordic strain] (multivalent) vaccine + ebola [adenovirus serotype 26] (monovalent) vaccine – Drug Profile
- Ebola [strain Sudan] vaccine – Drug Profile
- Ebola [strains Sudan + Zaire] (bivalent) vaccine – Drug Profile
- Ebola [Zaire] vaccine – Drug Profile
- ebola vaccine – Drug Profile
- Ebola vaccine 1 – Drug Profile
- Ebola Zaire vaccine – Drug Profile
- EBOTAb – Drug Profile
- FBH-004 – Drug Profile
- FDX-000 – Drug Profile
- Fibrinoplate-S – Drug Profile
- filovirus vaccine – Drug Profile
- galidesivir – Drug Profile
- Gamezumab – Drug Profile
- Gene Therapy for Ebola Virus Infections – Drug Profile
- GEOEM-01 – Drug Profile
- GreEMTri – Drug Profile
- GSK-3390107A – Drug Profile
- hemorrhagic fever vaccine – Drug Profile
- infectious disease vaccine – Drug Profile
- INO-4201 – Drug Profile
- IPT-002 – Drug Profile
- KM-219 – Drug Profile
- LB-2 – Drug Profile
- mAb-100 – Drug Profile
- MBP-134 – Drug Profile
- MBX-2806 – Drug Profile
- molnupiravir – Drug Profile
- Monoclonal Antibodies for Ebola Viral Infections – Drug Profile
- Monoclonal Antibodies for Ebola Virus Infections – Drug Profile
- Monoclonal Antibodies for Ebolavirus Infections – Drug Profile
- Monoclonal Antibody 1 for Ebolavirus Infections – Drug Profile
- Monoclonal Antibody for Ebola Viral Infections – Drug Profile
- Monoclonal Antibody for Ebolavirus Infections – Drug Profile
- Monoclonal Antibody for Zaire Ebolavirus Infections – Drug Profile
- MTX-113 – Drug Profile
- NCK-8 – Drug Profile
- NP-026 – Drug Profile
- PBI-05204 – Drug Profile
- PPCM – Drug Profile
- pyronaridine tetraphosphate – Drug Profile
- quinacrine hydrochloride – Drug Profile
- ranpirnase – Drug Profile
- RBT-05 – Drug Profile
- remdesivir – Drug Profile
- REVC-140 – Drug Profile
- SAB-139 – Drug Profile
- SLV-213 – Drug Profile
- Small Molecule 1 for Ebola Viral Infection – Drug Profile
- Small Molecule 2 for Ebola Viral Infection – Drug Profile
- Small Molecule 3 for Ebola Viral Infection – Drug Profile
- Small Molecule for Ebolavirus Infections – Drug Profile
- Small Molecules 1 for Ebolavirus Infections – Drug Profile
- Small Molecules for Ebola and Marburg Infections – Drug Profile
- Small Molecules for Ebola and Zika Viral Infections – Drug Profile
- Small Molecules for Ebola Viral Infections – Drug Profile
- Small Molecules for Ebolavirus Infections – Drug Profile
- Small Molecules for Infectious Disease – Drug Profile
- Small Molecules for Viral Infections – Drug Profile
- Small Molecules to Antagonize Glucocorticoid Receptor for Viral Infections – Drug Profile
- Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections – Drug Profile
- Small Molecules to Inhibit NPC1 for Ebola Viral Infections – Drug Profile
- Small Molecules to Inhibit Nucleoprotein for Ebola Virus Infections – Drug Profile
- Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections – Drug Profile
- Sudan Ebola virus vaccine – Drug Profile
- SW-456 – Drug Profile
- TCB-210 – Drug Profile
- tilorone hydrochloride – Drug Profile
- TNX-3500 – Drug Profile
- TriFiloVax – Drug Profile
- UMB-18 – Drug Profile
- XAV-2 – Drug Profile
- ZMAb – Drug Profile
- Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects
- Ebolavirus Infections (Ebola Hemorrhagic Fever) – Discontinued Products
- Ebolavirus Infections (Ebola Hemorrhagic Fever) – Product Development Milestones
- Featured News & Press Releases
- Dec 02, 2021: Soligenix announces successful protection using a bivalent thermostabilized filovirus vaccine
- Nov 16, 2021: INOVIO collaborates with GuardRX and Geneva University Hospitals for heterologous booster clinical trial of its ebola DNA vaccine candidate, INO-4201
- Oct 29, 2021: Statement on data published in PLOS Medicine on tolerability and immune response of Johnson & Johnson Ebola Vaccine regimen in adults living with HIV
- Oct 14, 2021: GeoVax receives notice of allowance for Ebola Vaccine patent
- Sep 14, 2021: J&J’s Ebola vaccine regimen offers robust immune response in Phase III trial
- Aug 23, 2021: Soligenix announces publication demonstrating successful formulation and heat stabilization of filovirus vaccine platform for Ebola and Marburg virus diseases
- Aug 18, 2021: Soligenix announces positive preclinical data with multiple heat stable filovirus vaccine candidates
- Jul 22, 2021: GeoVax announces presentation of Sudan ebolavirus vaccine data at the American Society for Virology Annual Meeting
- Jun 04, 2021: Statement on the SAGE Recommendation Regarding the Johnson & Johnson Ebola Vaccine Regimen
- May 17, 2021: Ebola vaccine regimen from Johnson & Johnson and Bavarian Nordic supports World Health Organization in efforts to prevent spread of Ebola in West Africa
- May 13, 2021: Johnson & Johnson joins World Health Organization in efforts to prevent spread of Ebola in West Africa
- Jan 07, 2021: Oyagen publishes study on its OYA1 as a highly effective experimental drug candidate for treating infections by the Ebola virus
- Jul 02, 2020: Janssen's Ebola vaccine secures European regulatory approval
- Jun 12, 2020: Bavarian Nordic to manufacture additional Ebola vaccines for Janssen
- May 29, 2020: Bavarian Nordic announces that Janssen has received positive CHMP opinion for its Investigational Preventative Ebola Vaccine Regimen
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Universities/Institutes, 2022
- Table 7: Products under Development by Companies, 2022
- Table 8: Products under Development by Companies, 2022 (Contd..1)
- Table 9: Products under Development by Companies, 2022 (Contd..2)
- Table 10: Products under Development by Companies, 2022 (Contd..3)
- Table 11: Products under Development by Companies, 2022 (Contd..4)
- Table 12: Products under Development by Universities/Institutes, 2022
- Table 13: Number of Products by Stage and Target, 2022
- Table 14: Number of Products by Stage and Mechanism of Action, 2022
- Table 15: Number of Products by Stage and Route of Administration, 2022
- Table 16: Number of Products by Stage and Molecule Type, 2022
- Table 17: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Abivax SA, 2022
- Table 18: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AIkido Pharma Inc, 2022
- Table 19: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AlphaVax Inc, 2022
- Table 20: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AnGes Inc, 2022
- Table 21: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by ANP Technologies Inc, 2022
- Table 22: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AntoXa Corp, 2022
- Table 23: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Arisan Therapeutics Inc, 2022
- Table 24: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Auro Vaccines LLC, 2022
- Table 25: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Bharat Biotech Ltd, 2022
- Table 26: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioComo Inc, 2022
- Table 27: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioCryst Pharmaceuticals Inc, 2022
- Table 28: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioFactura Inc, 2022
- Table 29: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Biotron Ltd, 2022
- Table 30: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Celdara Medical LLC, 2022
- Table 31: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Chicago Biosolutions Inc, 2022
- Table 32: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Cocrystal Pharma Inc, 2022
- Table 33: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Collaborations Pharmaceuticals Inc, 2022
- Table 34: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Emergent BioSolutions Inc, 2022
- Table 35: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Emergex Vaccines Holding Ltd, 2022
- Table 36: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Fab’entech SA, 2022
- Table 37: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Fibroplate Inc, 2022
- Table 38: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Flow Pharma Inc, 2022
- Table 39: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Fox Chase Chemical Diversity Center Inc, 2022
- Table 40: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Galactica Biotech Ltd, 2022
- Table 41: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Gamaleya Federal Research Center of Epidemiology and Microbiology, 2022
- Table 42: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by GeoVax Labs Inc, 2022
- Table 43: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Gilead Sciences Inc, 2022
- Table 44: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Global BioLife Inc Ltd, 2022
- Table 45: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Greffex Inc, 2022
- Table 46: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by H&P Labs Inc, 2022
- Table 47: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by ImmunityBio Inc, 2022
- Table 48: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Inovio Pharmaceuticals Inc, 2022
- Table 49: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Integral Molecular Inc, 2022
- Table 50: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Integrated BioTherapeutics Inc, 2022
- Table 51: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by IntelliStem Technologies Inc, 2022
- Table 52: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Johnson & Johnson, 2022
- Table 53: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Mapp Biopharmaceutical Inc, 2022
- Table 54: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Merck & Co Inc, 2022
- Table 55: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Microbiotix Inc, 2022
- Table 56: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Micropharm Ltd, 2022
- Table 57: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Novavax Inc, 2022
- Table 58: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Nykode Therapeutics AS, 2022
- Table 59: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Oita University Institute of Advanced Medicine Inc, 2022
- Table 60: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by OncXerna Therapeutics Inc, 2022
- Table 61: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Orgenesis Inc, 2022
- Table 62: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Ostrich Pharma USA Inc, 2022
- Table 63: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Palisades Therapeutics, 2022
- Table 64: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by PanThera Biopharma LLC, 2022
- Table 65: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Phelix Therapeutics LLC, 2022
- Table 66: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Phoenix Biotechnology Inc, 2022
- Table 67: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Public Health Vaccines LLC, 2022
- Table 68: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Table 69: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by ReVacc Biotech, 2022
- Table 70: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Riboscience LLC, 2022
- Table 71: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Rodos BioTarget GmbH, 2022
- Table 72: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by SAB Biotherapeutics Inc, 2022
- Table 73: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2022
- Table 74: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Selva Therapeutics Inc, 2022
- Table 75: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, 2022
- Table 76: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Soligenix Inc, 2022
- Table 77: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by TFF Pharmaceuticals Inc, 2022
- Table 78: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Tiba Biotech LLC, 2022
- Table 79: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
- Table 80: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Uvax Bio LLC, 2022
- Table 81: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Vaxeal Holding SA, 2022
- Table 82: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Vir Biotechnology Inc, 2022
- Table 83: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by XBiotech Inc, 2022
- Table 84: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Xenothera SAS, 2022
- Table 85: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Yaso Therapeutics Inc, 2022
- Table 86: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Yisheng Biopharma Co Ltd, 2022
- Table 87: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Zalgen Labs LLC, 2022
- Table 88: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2022
- Table 89: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2022 (Contd..1)
- Table 90: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2022 (Contd..2)
- Table 91: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2022 (Contd..3)
- Table 92: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2022 (Contd..4)
- Table 93: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2022 (Contd..5)
- Table 94: Ebolavirus Infections (Ebola Hemorrhagic Fever) – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.